Inozyme Pharma has a Cash Ratio of 3.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Inozyme Pharma's Cash Ratio or its related term are showing as below:
INZY'
s Cash Ratio Range Over the Past 10 Years
Min: 3.34 Med: 12.84 Max: 18.07
Current: 3.34
During the past 7 years, Inozyme Pharma's highest Cash Ratio was 18.07. The lowest was 3.34. And the median was 12.84.
INZY's Cash Ratio is ranked better than 55.39% of 1466
companies
in the Biotechnology industry
Industry Median: 2.715
vs INZY: 3.34
Inozyme Pharma Cash Ratio Historical Data
The historical data trend for Inozyme Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inozyme Pharma's Cash Ratio
For the Biotechnology subindustry, Inozyme Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inozyme Pharma's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Inozyme Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inozyme Pharma (NAS:INZY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Inozyme Pharma Cash Ratio Related Terms
Thank you for viewing the detailed overview of Inozyme Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INZY has been successfully added to your 